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Abstract
The sequential interaction of the envelope glycoprotein of the human immunodeficiency virus type 1 (HIV-1) with CD4 and
certain chemokine coreceptors initiates host cell entry of the virus. The appropriate chemokines have been shown to inhibit
viral replication by blocking interaction of the gp120 envelope protein with the coreceptors. We considered the possibility
that this interaction involves a motif of the gp120 that may be structurally homologous to the chemokines. In the amino
acid sequences of most chemokines there is a Trp residue located at the beginning of the C-terminal a-helix, which is
separated by six residues from the fourth Cys residue. The gp120 of all HIV-1 isolates have a similar motif, which includes the
C-terminal part of a variable loop 3 (V3) and N-terminal part of a conserved region 3 (C3). Two synthetic peptides, derived
from the relevant gp120 sequence inhibited HIV-1 replication in macrophages and T lymphocytes in sequence-dependent
manner. The peptides also prevented binding of anti-CXCR4 antibodies to CXCR4, and inhibited the intracellular Ca
2+ influx
in response to CXCL12/SDF-1a. Thus these peptides can be used to dissect gp120 interactions with chemokine receptors
and could serve as leads for the design of new inhibitors of HIV-1.
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Introduction
The envelope glycoprotein of the human immunodeficiency virus
type 1 (HIV-1) mediates the fusion of viral and host cell membranes
necessary for virion entry [1]. The envelope glycoprotein of HIV-1
is produced by the enzymatic cleavage from the gp160 precursor
protein with formation of the external gp120 and the transmem-
brane gp41 proteins [2]. Several studies have identified the amino
acid residues of gp120 that are responsible for the specific
interaction with CD4, the primary receptor for HIV-1 [3–6]. It is
likely that a conformational change occurs in gp120 following the
binding to CD4, and this exposes a binding site(s) for the chemokine
receptor/viral coreceptor [5]. The major viral coreceptors are
CXCR4, the receptor for stromal derived factor-1 (CXCL12/SDF-
1a), and CCR5, a receptor for several chemokines including
macrophage inflammatory protein-1b (CCL4/MIP-1b) [7]. Recent
studies suggest that the association of the CD4-gp120 complex with
the viral coreceptor leads to a rearrangement of gp120 that allows
the interaction of the gp41 envelope protein subunit with the host
cell membrane and viral entry [8,9]. Since chemokine receptors
have presumably evolved for the selective binding of chemokines,
we proposed that a region of the viral glycoprotein gp120, res-
ponsible for recognition of coreceptors, might have a structural
element similar to that found in the respective chemokine ligand. In
theaminoacid sequencesofmost chemokines, thereisa Trp residue
located at the beginning of C-terminal a-helix that is separated by
six residues from the fourth Cys residue. The gp120 of all HIV-1
isolates have a very similar motif adjacent to the V3 loop. We
hypothesized that this region of gp120 may directly interact with
chemokine receptors. The synthesized peptides based on the rele-
vant gp120 sequence were found to interfere with chemokine
receptor function and inhibit HIV replication in susceptible cells.
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Synthetic peptides
Peptides 15D, 15K and 15KS were synthesized by Macromo-
lecular Resources (Fort Collins, CO). The peptides were purified
by reverse-phase HPLC, and their homogeneity was confirmed by
mass-spectrometry.
Computer modeling
A model of the gp120 fragment (residues 331–340) was derived
by superimposing heavy atoms onto the corresponding heavy
atoms of CCL4 residues 51–60, which is in a helical conformation
(the atomic coordinates were obtained from X-ray structure of
CCL4, pdb code 1 hum). Starting with a helical conformation of
the gp120 fragment, backbone atoms and homologous side chain
atoms were template forced onto the CCL4 structure during this
protocol. The resulting gp120 model helix was optimized using a
constrained protocol of sampled molecular dynamics structures
followed by conjugate gradients minimization and selection of
minima under a consistent valence force field (CVFF) [10–12].
Cells and culture conditions
CEMx174 cell line was obtained from ATCC (Rockville, MD).
HEK293/CXCR4 and HEK293/CCR5 cell lines were kindly
provided by O.M.Zack Howard [13]. Cells were cultured in RPMI-
1640 medium (BioWhittaker, Walkersville, MD) containing 10%
fetal bovine serum (FBS; HyClone, Logan, UT), 2 mM glutamine,
100 units/ml penicilin and streptomycin (Quality Biologicals,
Gaithersburg, MD) at 37uC in a humidified 5% CO2 atmosphere.
Preparation of monocytes, monocyte-derived
macrophages and T cells
Peripheral blood mononuclear cells (PBMCs) were obtained
from the whole blood of seronegative donors and isolated by
Ficoll-Paque Plus (Pharmacia Biotech, Piscataway, NJ) using
standard density gradient centrifugation techniques. Enriched
populations of monocytes or CD4-positive T cells were prepared
by magnetic bead separation using anti-CD14 or anti-CD4
microbeads (Miltenyi Biotec, Inc, Auburn, CA) in RPMI-1640
medium supplemented with 10% heat-inactivated, low-endotoxin
fetal calf serum (Hyclone Laboratories, Logan, UT), 10 mg/mL
gentamicin, and 1 mM L-glutamine.
Monocyte-derived macrophages (MDM) were generated from
adherent human peripheral blood mononuclear cells by culture for
7 days with M-CSF (100 ng/ml). Cultures were maintained in
RPMI-1640 medium (Life Technologies, Rockville, MD) supple-
mented with 10% heat-inactivated endotoxin-free FCS (Hyclone,
Logan, UT), 10 mg/ml gentamicin, and 1 mM glutamine.
There was no toxicity detected for any of the peptides using
trypan blue dyeexclusion. Cells treated at eachdose of peptide were
assessed for evidence of toxicity at 4 hours and 3 days following
peptide administration, at each dose employed. We observed no
detectable cytotoxicity of the peptides on the cells even at 50 mM
concentration.
HIV-1
The R5 JRFL and X4 IIIB strains of HIV-1 were obtained from
the National Institute of Allergy and Infectious Diseases AIDS
Research and Reference Reagent Program (Rockville, MD). The
JRFL virus strain was propagated in cultures of peripheral blood
mononuclearcells(PBMCs)fromadultdonors.TheIIIBvirusstrain
was propagated in the human T-cell line, Molt-4 and puri-
fied from the supernatants, and stored in aliquotsat -85C. Virus was
concentrated from culture supernatants and purified by pelleting at
110,000 g for 90 min. This procedure produces stock virus of
between 10
6 and 10
7 syncytia forming units per 0.1 ml. The pellets
weregentlywashedandresuspendedinmedium.Themultiplicityof
infection(MOI)ofthe IIIBstrainisdeterminedbycountingsyncytia
formed by HIV-infected lymphocytes when co-cultured with
exponentially growing CD4-bearing SupT1 cells. The 50% tissue
culture infectious dose (TCID50) for the M-tropic virus is
determined using PBMCs. In all infectivity experiments cells were
infected with HIV-1 at a multiplicity of infection (MOI) of 0.1.
HIV-1 strong-stop expression
The effect of peptide administration on HIV-1 replication in
designated experiments was assessed by PCR quantification of
strong-stop proviral R/U5 long-terminal repeat structures as des-
cribed by Cole et al. [14], with minor modification. Briefly, DNA
isolated 4 hours after infection was amplified with HIV-1 R/U5
primers 59-CAAGTAGTGTGTGCCCGTCTGT-39 and 59-CT-
GCTAGAGATTTTCCACACTGAC-39, which correspond to
nucleotides 560-581 of the R region, and nucleotides 612-635 of
the U5 region. The PCR amplification of strong-stop DNA was
quantitated using DNA isolated from chronically-infected (HIV-1
strain IIIB) human T cells as a standard, using the VB thymocyte
cell line. In each case, the DNA isolation efficiency was controlled
by quantitation of b-globin DNA. Data were analyzed for statistical
significance using one-way analysis of variance.
HIV-1 59 LTR expression
The effect of peptide administration on HIV-1 reprlication was
also assessed by PCR quantitification of 59LTR synthesis, using a
method described by Szabo et al. [15]. Briefly, DNA was isolated
at the designated times following infection, and PCR was used to
amplify a 342 bp region of the 59 LTR of HIV-1 uisng oligo-
nucleotide DNA primers 59-AGCCTCAATAAAGCTTGCCT-39
and 59-CCCCCTGGCCTTAACCGAAT-39, followed by elec-
trophoresis in 1.5% agarose gel, and transfer to positively charged
nylon membranes for Southern blot analysis. An oligonucleotide
probe(59-GGAGAGAGATGGGTGCGGAG-39)was59end-labeled
with [c-
32P]ATP (DNA 59 End-Labeling System, Promega Corpora-
tion, Madison, WI). The membrane was incubated for 2 hr at 37uC
in a rotary hybridization incubator with prehybridization solution
(6X SSC, 5X Denhardt, 0.05% NaPPi, 100 mg/ml herring sperm
DNA, and 5–10 ml probe), and washed five times with washing
buffer (6X SSC plus 0.05% NaPPi) the next day. The membrane
was exposed to Biomax-MR film, and the film was analyzed by
autoradiography. Quantitation of the bands was carried out using
10-fold dilutions of the latently-infected ACH-2 cell line.
p24-based infectivity assay
Cells were treated with designated concentrations of the pep-
tides 15K or 15D, and after 1 h cells were infected with HIV-1JRFL
( m o n o c y t et r o p i c )a ta nM O Io f0 . 1 .A f t e r2h ,c e l l sw e r ew a s h e d ,a n d
cultured for additional 48–72 h, followed by analysis of HIV
replication by determination of accumulated p24 in the supernatant.
The production of p24 was determined by a sandwich ELISA, using
ELISA plates pre-coated with capture anti-p24 anti-
bodies provided by the AIDS Vaccine Program (SAIC Frederick,
NCI-FCRDC, Frederick, MD). The captured p24 antigen was
detected using rabbit anti-HIV-1 anti-p24 antibody, and a secondary
goat anti-rabbit IgG (peroxidase-labeled) antibody. The captured p24
protein was detected using 3,39,5,59-tetramethylbenzidine and hydro-
gen peroxide detection system (KPL Laboratories, Gaithersburg, MD).
The reaction was read spectrophotometrically at 450 nm. Data were
analyzed for statistical significance using one-way analysis of variance.
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expression after treatment of cells with peptides
CEMx174 cells were pelleted and resuspended at 10
6 cells/ml
in PBS containing 1% BSA and 0.1% sodium azide (FACS buffer).
Cells were then preincubated with designated concentrations of
peptides or CXCL12 (1 mg/ml) at 22uC for 60 min. FITC-labeled
anti-human CXCR4 antibody (clone 12G5, BD PharMingen) was
added to the cells per the manufactures instructions and further
incubated at 22uC for 40 minutes. Cells were extensively washed
with FACS buffer and analyzed using a FACS Calibur flow-
cytometer (Becton Dickinson). HEK/CCR5 cells were suspended
in Dulbecco’s PBS containing 1% FCS and 0.05% NaN3 (10
4 cells
in 100 ml) and incubated with or without 5 mg of CCL4
(PeproTech, Rocky Hill, NJ), 0.1 mM peptide 15D or 15K for
45 min at 22uC. Cells were then treated with FITC-conjugated
anti-human CCR5 antibody (2D7; BD PharMingen), and incu-
bated for 30 min at 22uC. Cells were washed twice, and analyzed
using a FACS Scan flow cytometer (Becton Dickinson).
Chemokine binding assay
Binding assays were performed with the CCR5-expressing
174xCEM and Sup-T1 cell lines by adding unlabeled competitor
(peptide or control chemokine) and radiolabeled chemokine,
0.2 ng/ml
125I-MIP-1bor SDF-1 aspecific activity 2000 Ci/mmol,
NEN Life Science Products) to cells in a binding medium
consisting of RPMI 1640 supplemented with 1% bovine serum
albumin, 0.1% sodium azide and 25 mM HEPES pH 8.0. Cells
were then incubated at 22uC for 30 min with continuous rotation.
After incubation, cells were centrifuged through 10% sucrose in
PBS, and the supernatant was aspirated and the cell-associated
radioactivity was determined. The data were analyzed by
nonlinear regression using GraphPad Prizm 3.0.
Microscope-based Calcium-flux assay
Microscope based ratiometric analysis was performed as described
by Zhang, et al. [16] with minor modifications. CXCR4/HEK293
cells were cultured in eight-well chambered cover glass slides (Nunc,
IL) for 24–48 hours. Before the experiments, cells were incubated for
45 min with FURA-2 (Molecular Probes) in complete DMEM
medium, followed by three washes with calcium saline buffer
(138 mM NaCl, 6 mM KCl, 1 mM CaCl2, 1 mM MgCl2,
5.5 mM glucose, 0.1% bovine serum albumin, pH 7.4). Peptides
(15K and 15KS) or CXCL12 were diluted in PBS to appropriate
concentrations. Ratiometric calcium imaging was performed using a
Nikon Eclipse TE200 fluorescence microscope equipped with a
variablefilter wheel (Sutter Instruments, Novato, CA),a Spot charge-
coupled device camera, and a Nikon S Fluor 40X objective lens.Dual
images (340 and 380 nm excitation, 510 emission) were collected by
Table 1. Amino acid alignment of sequences of gp120 of some HIV-1 strains with CCL4 and CXCL12.
V3 V3 V3 V3 V3 V3 C3 C3 C3 C3 C3 C3 C3 C3 C3
HIV-1 strain
a
HXB2 M RQ AHC NI SRAKW NN
326 340
IIIB M RQ AHC NI SRAKW NA
326 340
JRFL I RQ AHC NI SRAKW ND
322 336
Consensus A I RQ AHC NVSRSEW NK
310 324
Consensus B I RQ AHC NI SRAQW NN
322 336
Chemokine
CCL4 S KQ -V C ADPSESW VQ
47 60
CXCL12 N RQ -V C ID P K L KW IQ
46 59
aThe residues numbered according to Korber (1998). The residues identical in HIV-1 gp120 and chemokines are shown in bold. The location of the residues relative to
the V3 loop/C3 region is noted.
doi:10.1371/journal.pone.0014474.t001
Table 2. Sequences of synthesized peptides.
P e p t i d e 1234567891 0 1 1 1 2 1 3 1 4 1 5
15 K I RKAHCNI SRAKWND
15 D I RKAHCNI SRADWND
15 KS KI NSWRADNI HCKAR
15GIG GI GDPVTCLKSGAI A
doi:10.1371/journal.pone.0014474.t002
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ratiometric images were monitored every four seconds. Cells were
incubated with PBS, 15K (1.8 mM), or 15KS (1.8 mM) for 12
seconds, followed by a stimulation by CXCL12 (15 nM) at 24
seconds.
Chemokine production in PBMCs
PBMCs were cultured in RPMI-1640 medium supplemented
with 10% fetal calf serum, and peptides were added at the
designated concentrations. At 24, 48, 72 and 96 h, the supernatants
were collected, and tested for the level of CCL2, CCL3, CCL4,
CCL5 and CXCL12 by ELISA. Values represent the mean (6 SD)
of triplicate cultures, and the results are representative of 3 different
donors.
Results
Amino acid homology between gp120 and chemokines
We noticed that in the amino acid sequences of most CC and
some CXC chemokines there is a Trp residue located at the
beginning of C-terminal a-helix, and separated by six residues
from the fourth Cys residue. In the amino acid sequences of gp120
of all HIV-1 isolates there is a very similar motif in conserved
region 3 (C3) adjacent to the V3 loop [17]. Moreover, several
residues of the C-terminal part of variable loop 3 (V3) are also
conserved between different HIV-1 strains and exhibit some
homology with the chemokines (Table 1).
Computer modeling of HIV-1 gp120 fragment based on
the structure of CCR5 ligand CCL4
To assess the possibility that this particular fragment of gp120
may potentially assume a structure similar to that of chemokines, a
model of the corresponding structure of gp120 was built using the
structure of CCL4 [18] as the template. Under the constraints of
the CVFF molecular mechanics force field, such a model of the
three-dimensional structure of this gp120 segment could be generated
without violation of protein stereochemistry. The resulting structure
possessed the same helical character as the protein backbone of
CCL4with a root mean square (RMS) deviation of the superim-
posed backbone atoms of 0.26. In an effort to examine the func-
tional activity of this region we synthesized peptides corresponding
to the gp120 sequence for further studies.
Rationale for design of inhibitory peptides
The synthesized peptides corresponding to sequences of gp120
homologous to chemokines are shown in Table 2. The sequence of
HIV-1JRFL, which is very close to the consensus B of HIV-1
sequences [17], was used as a template for the design of anti-HIV
peptides. Because gp120 of different HIV-1 strains have some
sequence variability even in conserved regions, we designed
peptides with sequences similar to the widest range of naturally
existing variants. In many HIV strains there is a lysine residue
instead of glutamine in position 3 (Table 2). Moreover, it was
reasonable to change glutamine for lysine in the synthetic peptide
to avoid hydrolysis and conversion to glutamic acid near the
conserved positively charged arginine. The corresponding peptide
was designated 15K. In another peptide the lysine-12 preceding
tryptophan was changed to aspartic acid (peptide designated 15D)
because some HIV-1 isolates have aspartic acid in this position
and we wished to explore the significance of this substitution. For
control experiments, a scrambled peptide 15KS with the same
amino acid composition as 15K was also employed. In designated
control experiments a 15 amino acid peptide GIG, with an amino
acid sequence unrelated to gp120 or chemokines, was also used.
Effect of the 15K and 15D peptides on HIV-1 infection
Our computer modeling of the conserved region of gp120
suggested that the peptides 15K and 15D might block the ability of
CCR5 to serve as an HIV-1 co-receptor. We determined the
capacity of the peptides to inhibit infection of CD14+ monocytes
by HIV-1JRFL, a monocyte-tropic HIV-1 strain, using PCR
quantification of strong-stop proviral R/U5 long-terminal repeat
structures [14]. Our results (Figure 1A) show that the addition of
either 15K or 15D to the cells reduces infection with HIV-1, with
significant inhibition at concentrations as low as 50 nM. The
scrambled peptide 15KS with the same amino acid composition
as 15K but a randomized sequence (Table 2) manifested no
inhibition of virus infectivity demonstrating the importance of the
Figure 1. Inhibition of HIV-1 infection by peptides 15K, 15D,
and the scrambled peptide 15KS using HIV-1 strain JRFL
infection of purified monocytes (Panel A) or PBMCs (Panels
C&E), or HIV-1 strain IIIB infection of purified CD4-positive T
cells (Panel B) or PBMCs (Panel D&F). Cells were treated with the
designated concentrations of peptide for a period of 1 h prior to
addition of HIV-1 at an MOI of 0.1, or 500 nM peptide in Panels E&F.
Four h after infection the cells were harvested and the HIV early
replication was determined by PCR quantification of either strong-stop
proviral R/U5 long-terminal repeat structures (Panels A& B), or at 18 hrs
for the measurement of the 59LTR (Panels C&D). The expression of HIV-1
p24 was also determined as a measure of HIV replication (Panels E&F).
Results are presented for a representative experiment except for the
data in Panels C and D where the collective data for all experiments are
presented as the mean 6 SD for each data point.
doi:10.1371/journal.pone.0014474.g001
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obtained essentially the same results from experiments in where
the expression of the HIV 59LTR was determined (Figure 1C)
following infection of PBMCs.
Based on the homology of the 15K and 15D peptides to the
CXCR4 ligand CXCL12, we also wished to determine the capacity
of the peptides to inhibit CXCR4 co-receptor function. Experi-
ments were carried out to assess the ability of 15K or 15D to alter
the infection of PBMCs with the T cell-tropic HIVIIIB strain. Our
results show that both peptides significantly reduced HIV-1
infection in a dose-dependent manner (Figure 1B). Significant
inhibition of the HIV-1 infection was detected with concentrations
of peptides as low as 5 nM. The scrambled peptide 15KS with the
same amino acid composition as 15K but a randomized sequence
(Table 2) manifested no inhibition of virus infectivity demonstrating
the importance of the particular amino acid sequence for inhibitory
activity. Here again, we obtained essentially the same results from
experiments in which we determined the expression of HIV 59LTR
following infection of PBMCs. The virus inhibition data suggest
that CXCR4-specific virus IIIB is more sensitive to peptides 15K
and 15D than CCR5-specific virus JRFL (Figure 1B vs 1A, and
Figure 1D vs 1C) probably because of higher affinity of interaction
of the peptides with CXCR4 than CCR5. Finally, we also assessed
the inhibition of HIV replication in PBMCs over a 5 day period,
and the results show that the greatest inhibition is apparent for the
first 72 hours following infection (Figure 1E & 1F).
Since it was reported that CC chemokines effectively inhibit
HIV-1 infection of cells [19] we compared the ability of chemokine
CCL4 and peptides 15D and 15K to inhibit HIV-1 infection of
monocyte-derived macrophages using p24 based infectivity assay.
Both peptides exhibited inhibitory activities comparable with
CCL4 (Figure 2). Comparison of inhibition of HIV-1 infectivity in
monocytes was determined by measuring HIV-1 strong-stop DNA
(Figure 1A), and infectivity of macrophages determined by mea-
suring p24 concentrations shows more potent inhibition in the p24
expression assay. This probably reflects the difference between the
assays. The detected proviral DNA includes not only full size copies
but also shorter fragments which would not lead to synthesis of
complete viral RNA and viral proteins; the measurement of p24
level in infected cell supernatants reflects the presence of assembled
viral particles.
Effect of peptides on the binding of antibodies to CXCR4
and CCR5 expressing cells
To determine if peptides 15D and 15K interact directly with
chemokine receptors we studied the effect of these and control
peptides on the binding of anti-chemokine receptor antibodies to
CXCR4 and CCR5. The monoclonal antibody 12G5 recognizes
a conformational extracellular epitope on CXCR4. This
antibody blocks the infectivity of some X4 strains of HIV-1
Figure 2. Inhibition of HIV-1 strain JRFL infection of monocyte-
derived macrophages by peptides 15K, 15D and chemokine
CCL4. Monocyte-derived macrophages were treated with the desig-
nated concentrations of peptide for a period of 1 h prior to addition of
HIV-1JRFL. After 2 hr, cells were washed, and viral replication was
determined after 72 hr by p24 analysis. Results are representative of 4
independent experiments. The level of replication in the 15D and 15K
groups were significantly different (P,0.01) from the untreated group
at concentrations of 5 nM or more.
doi:10.1371/journal.pone.0014474.g002
Figure 3. Effect of peptides 15K, 15D and scrambled peptide
15KS on the binding of anti-CXCR4 antibody 12G5 to CEMx174
cells. A. Dose-dependent effect of peptide 15K in comparison with
CXCL12. B. The comparison of the effects of 15K and 15D. C. The
comparison of the effects of 15K and 15KS. Cells were preincubated at
22uC with peptides at designated concentrations or CXCL12 for 60 min.
Then cells were incubated with FITC-labeled anti-human CXCR4
monoclonal antibodies 12G5 for 40 min at 22uC and washed with
FACS buffer prior to flow cytometry.
doi:10.1371/journal.pone.0014474.g003
Novel HIV gp120 Peptides
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natural CXCR4 ligand [23]. Further, the binding of 12G5 to
CXCR4 receptor-expressing cells is prevented by anti-HIV
compounds [24]. Our results show that peptide 15K inhibited
the binding of the 12G5 antibody to CXCR4 expressing cells in
a dose-dependent manner (Figure 3A), and at a concentration of
25 mM approached the efficacy of CXCL12 at 0.7 mM. The
more acidic peptide 15D appeared to be less effective in
blocking of 12G5 antibody binding to CXCR4 (Figure 3B),
which is not surprising since the chemokine binding site of
CXCR4 includes several negatively charged residues [25]. To
determine the importance of the particular amino acid sequence
for the inhibitory activity of the peptides we compared the
effects of peptide 15K and the corresponding scrambled peptide
15KS on binding of 12G5 to CXCR4. The scrambled peptide
15KS manifested significantly less inhibitory activity in compar-
ison with 15K suggesting the importance of the specific peptide
sequence (Figure 3C).
The monoclonal antibody 2D7 binds to a conformational
epitope on CCR5, and inhibits Ca
2+ flux induced by CCL5.
This antibody also inhibits HIV infection in vitro [26] but not
the binding of gp120-sCD4 complexes to CCR5 expressing
L1.2 murine cells [27]. We tested the effect of peptides 15D and
15K on antibody binding to HEK293/CCR5 by flow
cytometry. No significant effect of peptides on anti-CCR5
binding was observed indicating that the peptides bind to an
epitope distinct from the antibody-binding site or their binding
affinity is not sufficient for effective competition with this
particular antibody.
Effects of peptides on induction of intracellular Ca
2+
concentration by CXCL12 in CXCR4/HEK293 cells
The increase of intracellular Ca
2+ concentration mediated
by a chemokine receptor in response to a cognate chemokine
is a reliable assay for measurement of chemokine agonist
activity. CXCR4/HEK293 cells express a high level of
CXCR4 and respond well to CXCL12 stimulation, so we
used these cells to determine whether peptide 15K could
block the activation of CXCR4. Preincubation of cells with
peptide 15K (at a concentration of 1.8 mM) for 12 seconds
almost completely inhibited the cellular response to CXCL12
implying direct interaction of the peptide 15K with chemokine
receptor. The control scrambled peptide 15KS was signifi-
cantly less effective at inhibiting the Ca
2+ mobilization
response suggesting the importance of the specific peptide
sequence (Figure 4).
Effect of gp120 derived peptides 15 K and 15D on binding
of chemokines to CCR5 and CXCR4 expressing cells
Since the 15K and 15D peptides were designed based on their
structural homology with a chemokine fragment, we wanted to
determine whether these peptides might exhibit binding activity for
Figure 4. Effect of peptides 15K and 15KS pre-treatment on the mobilization of intracellular Ca
2+ in CXCR4/HEK cells in response to
CXCL12. Cells loaded with Fura-2 were preincubated with peptides at a final concentration of 1.8 mM for 12 sec prior to stimulation with CXCL12
(15 nM).
doi:10.1371/journal.pone.0014474.g004
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of the peptides to compete with radiolabeled CCL4 or CXCL12 for
binding to cells expressing CCR5 or CXCR4, respectively. To
determine the effect of peptides on chemokine binding and to
exclude the contribution of chemokine internalization, we incubated
cells at room temperature in the presence of 0.1% sodium azide.
Under such conditions all cell-bound ligand could be removed by
rinsing the cells with 0.1 M Gly-HCl pH 2.5, excluding contribution
of internalization to the chemokine binding. The binding experi-
ments show that the peptides 15D and 15K competitively inhibited
chemokine binding to CCR5 (Figure 5A) and CXCR4 (Figure 5B)
although with low potency. The control 15-mer peptide 15GIG with
a unrelated amino acid composition manifested significantly lower
competing activity (Figure 5C). The binding experiments did not
reveal any significant difference in the inhibitory activity of peptide
15K in comparison with the scrambled analog (Figure 5D).
Induction of chemokine production in PBMC by peptides
15K and 15D
CCL3, CCL4, CCL5 and CXCL12 are important natural
inhibitors of HIV-1 infection, and it possible that the activation of
chemokine receptors may stimulate chemokine expression. The
production of these chemokines by in the cultures of peptide-
treated cells could contribute to the antiviral activity of the
peptides. In an effort to address this possibility, cells were treated
with peptides 15D and 15K and the chemokine levels were
determined by ELISA. Analysis of CCL2, CCL3, CCL4, CCL5
and CXCL12 in the cultures showed that only CCL2 levels were
elevated following peptide treatement, and the increase in CCL2
expression was observed primarily at 48 h post-peptide adminis-
tration (Figure 6). It appears unlikely that the production of
chemokines in the peptide-treated cultures could contribute to the
antiviral activity of the peptides.
Figure 5. Inhibition of chemokine receptor ligand binding by peptide pre-treatment. (A) Effect of pre-treatment with peptides 15K and
15D on the binding of CCL4 to SupT1/CCR5 cells; (B) Effect of pre-treatment with peptides 15K and 15D on the binding of CXCL12 to CEMx174 cells;
and (C) Effect of pre-treatment with 15K and control peptide 15GIG on the binding of CXCL12 to CEMx174 cells; (D) Effect of pre-treatment with
peptides 15K and 15KS on the binding of CXCL12 to CEMx174. Binding studies were performed as described in Materials and Methods.
doi:10.1371/journal.pone.0014474.g005
Figure 6. Induction of chemokine expression following peptide
administration. Cells were treated with 15K and 15D, at the
designated concentrations, and supernatants were collected from the
cultures at 48 h, and subjected to ELISA for the determination of CCL2,
CCL3, CCL4, CCL5 and CXCL12 levels. Levels of chemokine at 24, 72, and
96 h were also monitored for chemokine levels (data not shown). Data
are presented as the mean (6 SD) of triplicate determinations, and the
data are representative of the results from experiments with three
donors.
doi:10.1371/journal.pone.0014474.g006
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The interaction of HIV-1 envelope glycoprotein gp120 with a
chemokine receptor is a prerequisite for viral attachment and entry
into the target cell [7]. Monocyte-tropic viruses utilize chemokine
receptor CCR5 for cell entry (R5 strains) and T cell tropic virus
utilize CXCR4 (X4 strains). The chemokine receptor binding site
on gp120 is formed or exposed after binding of CD4 to gp120
[28]. However, the binding of the gp120 of certain HIV-1 strains
to the chemokine receptor does not require interaction with CD4
[29,30]. The V3 loop of gp120 has been identified as the major
determinant of cellular tropism and coreceptor specificity [31,32].
However, the precise region within this 35–37 amino acid loop
responsible for the observed coreceptor-usage phenotype has not
been established [33]. It was found that synthetic cyclized peptides
corresponding to the V3 loop of gp120 of X4 and dual strains of
HIV-1 (but not an R5 strain), at micromolar concentration, could
prevent binding of anti-CXCR4 antibodies. Some of these
peptides at micromolar concentrations inhibited the infectivity of
HIV-IIIB [34]. Synthetic polymeric preparations including a
putative V3 consensus sequence (GPGRAF) of HIV-1, were found
to inhibit HIV-1 infection by an unknown mechanism; however, it
is unlikely that this inhibition was due to competition with gp120
binding to the chemokine receptor or CD4 [35]. Although the
influence of V3 on HIV-1 coreceptor utilization is well established,
other more conservative regions of gp120 are also involved [36].
We reasoned that the localization of the chemokine receptor
binding site of gp120 might be identified based on similarity in
amino acid sequence with the chemokines. Indeed, we observed
that in the amino acid sequences of most chemokines there is a
Trp residue separated by six amino acid residues from the fourth
Cys residue. The gp120 of all HIV-1 isolates have a similar motif
in the C3 region following the V3 loop. Moreover, several residues
of the C-terminal part of the V3 loop also manifest some
homology with the chemokine sequence. Our computer modeling
demonstrated that this fragment of gp120 could be template forced
onto the homologous loop of the known three-dimensional
structure of CCL4 without violation of protein stereochemistry.
Importantly, our hypothesis that this particular fragment of
gp120 may interact with chemokine receptor similarly to a
chemokine is in agreement with published crystal structures of
gp120 and chemokines. The X-ray structure of an HIV-1 gp120
core (not including V-loops), complexed with a two-domain
fragment of CD4, and an antigen-binding fragment of neutralizing
antibody, was reported [5]. Although the structure does not
include variable loops of gp120 it did include the C3 portion of the
fragment of gp120, which we considered to be structurally similar
to the chemokines and potentially involved in interaction with
chemokine receptors. In fact, alignment of the three-dimensional
structure of this fragment (HIVHXB2, residues 331–340, Table 1)
with the corresponding fragment of CCL4 demonstrates that they
are similar (Figure 7). Both motifs are characterized by an a-helix
preceded by a turn. Both contain a Trp residue with the indole
ring buried in the interior region of the turn and with the a-carbon
present on an exterior turn of the helix. The surface residues on
the helices are characterized by long aliphatic side chains,
terminated with polar groups, including Lys, Glu, Gln, and Asn.
Moreover, this fragment is located within the region of gp120
molecule which was implicated in CCR5 binding [36].
Interestingly, when Sharon, et al. [37], determined the structure
of V3-MN peptide bound to Fv fragment of broadly neutralizing
monoclonal antibody 447-52D by NMR, it was found to have
conformational similarity to b hairpins in CCL4 and CCL5; the
structure of V3-IIIB peptide was similar to CXCL12. They
hypothesized that these structural differences in V3 loop of gp120
dictate which chemokine receptor a virus binds. The sequence
corresponding to our peptides is more conservative and might be
interacting with the sites of chemokine receptors, which are similar
between CC and CXC chemokine receptors.
At present it is assumed that the N-terminal region and the so
called N-loop following the first two cysteine residues of the
chemokines play the most important role in interaction with the
chemokine receptors, although apparently other parts of these
molecules contribute to receptor binding [38–40]. The C-
terminally truncated form of IL-8 missing the a-helix and b-turn
manifested greatly reduced chemotactic activity [38]. Additional
confirmation of the significance of this segment of chemokines for
receptor activation is provided by the observation that substitution
of Arg-45 and Arg-47 with Ser reduced the biological activity of
human CCL4 [41]. Finally, a peptide corresponding to the CCL-2
sequence just preceding the C-terminal a-helix, and its derivatives,
inhibited the recruitment of leukocytes to inflammatory sites in
animal models manifesting properties of broad spectrum chemo-
kine inhibitors [42]. This may imply that this site in chemokines is
Figure 7. Comparison of the structures of the fragments of
gp120 (HIVHXB2 residues 331–344, PDB code 1gc1) and CCL4
(residues 47–64, PDB code 1hum). Gp120 is shown in green and
CCL4 is in purple. The solvent interface in the context of both of the
whole proteins is to the right of the figure. The gp120 fragment was
rotated and side chain residues were allowed to move within the
constraints of the CVFF mechanics employed (see Methods: Computer
modeling) in order to align homologous amino acids. Both structures
exhibit a buried Trp residue at a turn preceding an a-helix which has
polar side chains on the surface. The location of the Trp in the start of
the helix and the hydrophobic nature of the residues surrounding the
Trp are also conserved features in both structures.
doi:10.1371/journal.pone.0014474.g007
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function in vivo. In a recent study it was demonstrated that the
residues including the beginning of the C-terminal a-helix of
CXCL12 could be involved in interaction with CXCR4 [43].
Since the peptides 15D and 15K include only 5 residues from
the C-terminal part of the V3 loop, which is more conserved than
other parts of V3 loop, and 9 residues from the N-terminal part of
the conservative C3 region, it was reasonable to expect that anti-
HIV activity of these peptides may not be dependent on virus
tropism. The effects of the peptides on infectivity of R5 and X4
viruses confirmed this prediction.
Our finding that peptides 15K and 15D compete with anti-
CXCR4 antibody 12G5 suggests a direct interaction of the peptide
with this receptor. Although the 15D peptide had reduced ability
to block binding of the 12G5 antibody, probably because it has a
negative Asp residue instead of Arg and it is known that the
chemokine binding site of CXCR4 is negatively charged, the
infectivity data indicate that the low-affinity interaction of 15D was
still sufficient to interfere with viral infection. It was established
[44] that MIP-1b and HIV-1 gp120 have overlapping but distinct
binding sites. Thus it is possible that our peptides based on gp120
sequence can more effectively compete with HIV-1 gp120
attached to virus than with the chemokine ligands. Moreover,
binding to CD4 induces a conformational change in virus-
associated gp120, which allows it to interact with chemokine
receptor [28]. This conformational state is very likely to be
transient, avoiding generation of neutralizing antibodies, and has a
limited time for productive interaction with the chemokine
receptors. Consequently, if the binding site for HIV-1 gp120 on
a chemokine receptor is occupied by our peptides it may have
strong inhibitory effect on virus infectivity. Apparently our
peptides are not strong competitors of chemokine binding, as
indicated by radio-labeled binding analysis, but have a signifi-
cantly slow rate of dissociation from receptor which would be
consistent with our calcium mobilization results, and would also be
consistent with the weak ability of chemokine to displace inhibitory
peptide from receptor immediately when chemokine is added. We
think that these two factors may explain rather strong antiviral and
low chemokine antagonistic activity of peptides. Of course more
studies are necessary to fully understand the mechanism of the
antiviral activity of these peptides.
When ligands such as free chemokines or HIV-1 gp120 interact
with chemokine receptors they can induce expression of additional
chemokines by the cells [45–47]. Thus a possible explanation for
potent inhibition of virus infectivity by our peptides could be
through the induction of chemokine production, which could
potentially inhibit virus attachment and infectivity. We failed to
detect the induction of CCL3, CCL4, CCL5 or CXCL12
following peptide administration (Figure 6). For this reason, we
find it unlikely that chemokine induction from the target cells by
the peptides during the infectivity assays played a significant role in
the observed antiviral activity.
The affinity of interaction of the peptides 15D and 15K with
chemokine receptors is apparently low. However, even this low
affinity interaction is sufficient for interference with HIV-1
infection based on the low concentration of peptides required for
blocking of the viral infection of macrophages and T lymphocytes.
The use of low affinity anti-viral drugs interfering with HIV-1
coreceptor interaction may allow targeting multiple cellular
coreceptors while maintaining the ability to inhibit interactions
of a viral glycoprotein, which is subject to frequent mutation.
Moreover, the rather weak competition of peptides 15D and 15K
with chemokines for receptor binding, together with potent
inhibition of HIV-1 infectivity, may be therapeutically preferable
to high affinity inhibitors of CXCR4 and CCR5, because these
peptides would not compromise functions of potentially critical
chemokines such as CXCL12 or the CCR5 ligands.
In conclusion, we believe that we identified a region of HIV-1
gp120, which appears to be structurally similar to chemokines, and
is probably directly involved in the interaction with certain
chemokine receptors. Our findings that the corresponding
peptides inhibit HIV-1 infection of human monocyte-derived
macrophages and T-lymphocytes at low nanomolar concentration
suggest that these peptides and their analogs may be used to dissect
gp120 interactions with different chemokine receptors and could
serve as leads for design of new peptide based inhibitors of HIV-1
not restricted by viral tropism [48]. Moreover, it may also be
possible that the antibodies raised against this sequence of HIV-1
gp120 may have anti-HIV protective and therapeutic activity.
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